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Abstract 
 Approximately 16.3% of the adult population in the United States maintains elevated 
levels of total cholesterol, and the components of the cholesterol profile—HDL, LDL, and 
triglyceride levels, among others—are particular determinants of cardiovascular disease risk. 
High levels of LDL in particular are associated with coronary atherosclerosis and cardiovascular 
disease. Conversely, high levels of HDL remove cholesterol from the blood and aid in 
metabolism. The HDL/LDL ratio is considered a marker of carotid plaque and is specifically 
used as an indicator for cardiovascular disease risk. Traditional cholesterol control treatment 
utilizes statin therapy and antihypertensive medication; however, recent trends toward alternative 
methods of treatment are making holistic cholesterol treatment programs more well-known. 
Using archival patient records at a holistic health cholesterol treatment program, this study 
investigates changes over the course of treatment in total cholesterol levels, the HDL/LDL ratio, 
and other cardiovascular health-related variables such as blood pressure, pulse rate, and weight. 
This study will provide a basis for future research investigating cardiovascular health from a 
holistic perspective, rather than examining these factors in isolation. 
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Cholesterol Levels and Cardiovascular Health Indicator Changes in a Holistic Health  
Treatment Program: An Archival Study 
The Centers for Disease Control and Prevention estimates that 16.3% of the adult 
population in the United States has high total cholesterol—defined as total cholesterol 240 
mg/dL and above (CDC, 2010). While the prevalence of high cholesterol in the adult 
demographic has been declining in recent decades (Schober, Carroll, Lacher, & Hirsch, 2007), 
this problem continues to be of significant economic and therapeutic concern; more than $300 
billion is spent on cardiovascular care each year in the United States (HHS.gov, 2011), and 
25.4% of deaths in 2007 were attributable to cardiovascular disease alone (CDC, 2007). 
Although the regulation of blood pressure levels may reduce the need for traditional cholesterol-
controlling medications (Green et al., 2002), those who maintain high levels of cholesterol 
sustain approximately twice the risk of coronary heart disease (CHD) as those with optimal 
levels (CDC, 2010). Low-density lipoprotein (LDL) cholesterol in particular leads to 
accumulated coronary atherosclerosis (Scann, 1978 in Tian et al., 2011). Thus, the components 
of the cholesterol profile—HDL, LDL, and triglyceride levels, among others—are particularly 
crucial to note when determining cardiovascular disease (CVD) risk. 
Treatment of Cholesterol 
Traditionally, elevated cholesterol levels have been treated with statin and 
antihypertensive regimens (Boden, 2003; Van der Harst & de Boer, 2010). However, current 
statin treatments focus on lowering LDL levels rather than on increasing HDL levels, and often 
produce undesireable side-effects (Anderson & Taylor, 2011; Rea, Durrant, & Boldy, 2002). 
While there has been demonstrated clinical improvement in cholesterol levels due to statin 
therapy, 60-70% of cardiovascular events are not prevented even with its use (Stroes, 2005). 
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Recently, there has been a trend towards a more holistic perspective of total body health, and 
holistic cholesterol treatment programs are becoming a viable alternative to traditional treatment 
(Guarneri, Mercado, & Suhar, 2009; Pratt, 2010). Holistic programs are extremely varied and 
differ from one program to another; however, focus is usually directed towards effecting lifestyle 
changes such as diet, exercise, and stress management rather than on the use of medications. The 
American Heart Association affirms that lifestyle changes such as these decrease cardiovascular 
disease morbidity and mortality risk (Artinian et al., 2010).  
Low-Density Lipoprotein 
 Low-density lipoprotein cholesterol (LDL) is a combination protein-and-lipid whose 
composition is low in protein and high in cholesterol, and which transports cholesterol from the 
liver to the body tissues. High levels of LDL in the body are a direct cause of accumulated 
coronary atherosclerosis (Scann, 1978 in Tian et al., 2011). In the United States, 33.5% of adults 
maintain elevated levels of LDL; only 48.1% of these are receiving treatment (Morbidity and 
Mortality Weekly Report, 2011). High levels of non-HDL cholesterol have been linked to 
increased coronary heart disease-related mortality, and incidence of stroke (Li et al., 2011). In 
patients diagnosed with diabetes, high non-HDL levels (i.e. levels greater than 5.3 mmol/L) were 
associated with a 40% increased risk of death from CHD (Laasko, Lehto, Penttila, & Pyorala, 
1993 in Li et al., 2011).  
High-Density Lipoprotein 
 High-density Lipoprotein cholesterol (HDL) is comprised of a relatively large proportion 
of protein and little cholesterol. As HDL removes cholesterol from the blood, prevents the 
cellular uptake of LDL, and aids in metabolism of other lipoproteins, high levels of serum HDL 
are associated with a reduced risk of CHD (Wilson et al., 1998 in Tian et al., 2011). One study 
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defined low levels of HDL as <40 mg/dL in men and <50 mg/dL in women (Ingelsson et al., 
2009). Although the National Cholesterol Education Program has not set a specific goal value for 
raising HDL levels, the limited HDL level-raising properties of statin medication may be of 
particular concern for the one-third of patients with CVD who have normal serologic LDL levels 
but low HDL levels (Melnikova, 2005). 
HDL/LDL Ratio 
 The HDL/LDL ratio is considered a marker of carotid plaque and cardiovascular health 
regardless of total cholesterol levels, and is used as a more accurate indicator for cardiovascular 
disease risk than LDL levels alone (Awano, 2010; Kannel, 2007, Millán et al., 2009). The 
HDL/LDL ratio is a strong predictor for subclinical atherosclerosis and carotid intima-media 
thickness progression (Enomoto et al., 2011). There is some evidence that the effectiveness of 
lipoprotein ratio profiles as an indicator of cardiovascular disease risk may differ by age 
(Paramsothy et al., 2010). While there is a growing trend towards using apolipoprotein levels as 
more accurate predictors of CVD risk than cholesterol levels, the HDL/LDL ratio is still 
considered a viable and standard method of assessing risk and cardiovascular health (Fernandez 
& Webb, 2008). 
The Program 
The holistic cholesterol and diabetes health program under study focuses on transforming 
lifestyle through dietary intake, exercise, moderation, outdoor activity, adequate rest, and trust in 
God. Patients are enrolled in an 18 day treatment program with individualized meal plans, an 
exercise regimen, physical therapy including water treatments and steam baths, and time for 
social interaction. Physical exams with a medical doctor are conducted throughout the program 
to assess changes over treatment. 
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Traditional treatment programs for cholesterol primarily utilize statin therapy and 
antihypertensive medication (Green, Kwok, & Durrington, 2002). However, there is growing 
evidence that balanced diets which include cereals, fruits, vegetables, and proteins improve 
cardiovascular health. Lifestyle factors such as diet have specifically been shown to have a 
measureable effect on plasma cholesterol levels (Howard et al., 2006). In one study, HDL 
improved more on a low–glycemic load diet (40% carbohydrate and 35% fat), and LDL 
concentration improved more on a low-fat diet (55% carbohydrate and 20% fat; Ebbeling et al., 
2007). Evidence has suggested that CHD progression responses to diet differ by gender, age, and 
initial cholesterol levels (Lapointe, Balk, & Lichtenstein, 2006; Uranga & Keller, 2010; Schober 
et al., 2007). Dietary intake of soy protein has been shown to reduce LDL levels and lessen the 
need for cholesterol-lowering treatments such as statin medications (Grunwald, Hoie, & Stier, 
2009). A diet rich in anti-oxidant vitamins, phytochemicals, folate, and dietary fiber provides 
“substantial additional benefits to diets low in saturated fatty acids” (Noakes, Clifton, & 
McMurchie, 1999, p. S3).  
The Study 
This study describes the outcomes of such a holistic program (name withheld for 
confidentiality), examines the relationships between cardiovascular health-related variables, and 
provides a basis for future research investigating these health markers from a holistic 
perspective, rather than in isolation. Specifically, this study evaluated the changes in total 
cholesterol levels and HDL/LDL ratios due to the holistic health treatment program, and 
identified demographic profiles and other cardiovascular health-related variables which are 
related to this change. This study examined the efficacy of alternative treatments, providing 
patients with elevated cholesterol a basis for choosing a holistic program. 
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Materials and Methods 
 This is an archival analysis of patient records collected during pre- and post-treatment 
physical exams. All data were collected over six years (1998-2003) using standardized patient 
charting procedures. Cholesterol, triglycerides, HDL and LDL levels (mg/dL), pulse rate (bpm), 
blood pressure (mmHg), weight (lbs), amount of exercise (miles/day), age (years), and gender 
were included in the analysis. All statistical tests were performed using PASW SPSS Statistics 
Student Version 18. All records were kept confidential as per the American Psychological 
Association’s Ethical Principles of Psychologists and Code of Conduct (APA.org, 2010). 
 The study population was composed of 901 patients (549 women, 352 men) enrolled in 
the program. Mean age of the sample was 60.80 years (SD = 15.26). Initial cholesterol and 
cardiovascular health variable data are listed in Table 1. In quite a few cases, some data points 
were missing from the archive; however, data were complete for all variables in 502 cases. Three 
relationships were analyzed in this study: change evidenced due to treatment, the relationship 
between total cholesterol and additional cardiovascular health variables, and the relationship 
between the HDL/LDL ratio and additional cardiovascular health variables. Variables were 
tested and analyzed using the t-statistic for independent samples, the t-statistic for paired 
samples, the Pearson Product-Moment Correlation Coefficient, and linear regression as 
appropriate. 
Results 
Significant differences between genders were seen for initial total cholesterol, HDL, 
LDL, the HDL/LDL ratio, and weight. Of these significant differences, men had higher 
triglyceride levels and initial weight than did women; however, women had higher total 
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cholesterol, HDL, LDL, and HDL/LDL ratio values. For a summary of gender differences in 
cardiovascular health variables at admittance, see Table 2. 
As the statistical results of this study are numerous and as analysis covers several topics, 
the results section of this report first details a summary of overall changes evidenced over the 
course of treatment. Following this, the relationships between cardiovascular-health related 
variables and (a) initial total cholesterol, (b) total cholesterol change, (c) initial HDL/LDL ratio, 
and (d) HDL/LDL ratio change are described. Total cholesterol levels are used as a reference 
marker and the HDL/LDL ratio is analyzed as an indicator of cardiovascular health and relative 
CVD risk.  
Overall Changes Evidenced 
 Over the course of the 18 day treatment, there was a significant improvement in all major 
cardiovascular health variables except HDL levels. Total cholesterol improved from M = 198.20 
mg/dL (SD = 46.58) to M = 174.50 mg/dL (SD = 42.21). Triglycerides dropped from M = 182.53 
mg/dL (SD = 118.47; kurtosis = 23.73) to M = 154.81 (SD = 76.25; kurtosis = 12.30); both initial 
and discharge triglyceride levels exhibited an unusually large kurtosis value, which indicated a 
large spread of triglyceride scores around the mean. Mean LDL levels decreased from 114.42 
mg/dL (SD = 36.92) to 98.25 (SD = 33.07). Contrary to expected trends, mean HDL levels also 
decreased from 47.94 mg/dL (SD = 14.18) to 45.34 mg/dL (SD = 13.25). However, the overall 
HDL/LDL ratio mean improved from 0.471 (SD = 0.23) to 0.514 (SD = 0.25). Upon regression 
analysis, this overall HDL/LDL ratio improvement and the concurrent decrease in both total 
cholesterol and in LDL levels explained 43% of the observed decline in HDL levels (R2 = .430, 
F(3, 699) = 177.204, SE = 5.749, p < .001; for a summary of interactions, see Table 3). 
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 Other cardiovascular health marker variables also improved over the course of treatment. 
Mean systolic blood pressure improved from 141.90 mmHg at admittance (SD = 24.50) to 
127.50 mmHg at discharge (SD = 19.85). Similarly, diastolic blood pressure decreased from 
admittance (M = 80.17; SD = 14.61) to discharge (M = 73.19; SD = 10.80). The mean amount of 
exercise in which patients engaged rose from 0.85 miles/day (SD = 1.44) at the beginning of 
treatment to 3.53 miles/day (SD = 2.26) by the end of the program. Over the course of the 18 day 
treatment, mean patient weight decreased from 206.10 lbs at initial evaluation (SD = 61.86) to 
200.33 lbs at discharge (SD = 59.06). All differences noted were statistically significant (see 
Table 4). 
Initial Total Cholesterol 
 Upon deeper analysis of total cholesterol dynamics, several relationships were noted 
between initial cholesterol levels and other holistic cardiovascular health variables. Initial 
cholesterol levels were analyzed by gender and age categories to see whether there was a 
significant difference between groups at the beginning of treatment. A significant gender 
difference for total initial cholesterol was present (t(837) = 4.988, p < .001); men had lower 
initial cholesterol levels (M = 187.33 mg/dL, SD = 47.03) than did women (M = 203.90 mg/dL, 
SD = 46.57). Additionally, cholesterol levels were compared by age groups (defined as 10 year 
increments from 20 to 99 years of age). Patients age 40-49 had the highest mean admittance 
cholesterol levels of any age group (n = 119, M = 204.06, SD = 60.96), and the second highest 
age group, those 50-59, had mean cholesterol levels of 203.64 mg/dL (n = 194, SD = 47.91). 
Patients ages 90-99 evidenced the lowest mean initial cholesterol (n = 7, M = 176.14, SD = 
56.07). For a summary of initial cholesterol age group differences see Figure 1.  
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Relationships with other cardiovascular health variables such as blood pressure, weight, 
and pulse rate were also analyzed to see whether any relationship existed between these variables 
and initial levels of cholesterol. These observed relationships describe the profile of those 
patients with higher admittance levels of cholesterol and evidence concurrent lower overall 
cardiovascular health markers as seen from a holistic perspective. Although positive 
relationships were noted between initial total cholesterol levels and several cardiovascular health 
markers, because of the large sample size and potential for exaggerated statistical significance 
only the most relevant effect size results are reported. The greatest effect sizes between initial 
cholesterol levels and cardiovascular health markers were seen for initial triglycerides (r(842) = 
.446, r2 = .199, p < .001) and initial LDL levels (r(793) = .884, r2 = .781, p < .001). These 
relationships indicated that initial cardiovascular levels explained 19.9% and 78.1% of observed 
initial triglyceride and LDL levels, respectively. Additionally, a negative relationship was 
observed between initial total cholesterol and the initial HDL/LDL ratio (r(792) = -.433, r2 = 
.187, p < .001). Patients with higher initial levels of cholesterol experienced limited 
improvement in triglycerides (r(761) = -.292, r2 = .085, p < .001) and LDL levels (r(703) = -
.370, r2 = .137, p < .001) when compared with those who had lower initial cholesterol levels. 
Relationships between initial total cholesterol and initial systolic blood pressure, initial weight, 
HDL change, pulse rate change, and systolic and diastolic blood pressure changes did not reach 
significance at the α = .01 level. For a correlations matrix see Table 5. 
Total Cholesterol Change 
 When determining the efficacy of a treatment program, the amount of total cholesterol 
change evidenced over the course of treatment is certainly important; however, when such a 
treatment program is viewed from a holistic perspective, an integrated analysis of the 
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relationship between total cholesterol change and other cardiovascular health-related variable 
changes is even more crucial. Over the course of treatment, mean cholesterol levels dropped by 
23.70 mg/dL (SD = 32.29) from 197.61 mg/dL at admittance (SD = 47.31) to 174.50 mg/dL at 
discharge (SD = 42.13). Patients ages 30-39 saw the greatest drop in cholesterol levels (M = -
34.96, SD = 34.89) followed by patients ages 50-59 and 40-49. For a summary of total 
cholesterol change differences by age group see Figure 2. Improvement in cholesterol levels was 
significantly greater (t(756) = 4.265, p < .001) for men (M = -30.11, SD = 32.41) than for women 
(M = -19.93, SD = 31.52). 
 Although several statistically significant relationships between cholesterol change and 
cardiovascular health marker changes were observed, the greatest correlated effect sizes between 
cholesterol change and cardiovascular health-related variables were seen for triglyceride change 
(r(761) = .472, r2 = .223, p < .001), and LDL change (r(703) = .834, r2 = .696, p < .001). This 
analysis indicated that initial cardiovascular levels explained 22.3% of observed triglyceride 
changes, and 69.6% of observed LDL level changes. Interestingly, a negative relationship was 
observed between total cholesterol change and the HDL/LDL ratio change (r(702) = -.469, r2 = 
.220, p < .001); as total cholesterol change was greater, the HDL/LDL ratio improvement was 
less marked. However, even with this relationship, mean HDL/LDL ratio improvement over the 
course of treatment was .047 (SD = .16) from M = .471 at admittance (SD = .23) to M = .514 at 
discharge (SD = .24). 
Initial HDL/LDL Ratio 
 As a marker for cardiovascular health, the initial HDL/LDL ratio was examined in 
conjunction with demographic and other cardiovascular health-related variables in order to 
describe the medical profiles of patients at admittance. Initial mean HDL/LDL ratio values (M = 
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.471, SD = .23) indicated an approximate 1.00 mg/dL HDL : 2.12 mg/dL LDL concentration at 
admittance. HDL/LDL ratios were significantly (t(786) = 3.516, p < .001) worse in men (M = 
.437, SD = .21) than in women (M = .494, SD = .24) at admittance. There were no significant 
ratio differences between age groups (F(7, 771) = 2.009, p = .052). A relationship was observed 
between the initial HDL/LDL ratio and HDL levels at admittance (r(792) = .623, r2 = .388, p < 
.001). A significant relationship was also noted between initial HDL/LDL ratio and LDL change 
over the course of treatment (r(703) = .353, r2 = .125, p < .001). Those with higher initial 
HDL/LDL ratio values experienced greater improvements in LDL during treatment; however, 
mean change in LDL regardless of initial HDL/LDL profile was M = -16.16 mg/dL (SD = 
23.36), and decreased from 114.42 mg/dL at admittance (SD = 36.92) to 98.25 mg/dL at 
discharge (SD = 33.07). For a correlation matrix including variables with effect sizes less than 
10% see Table 5. 
HDL/LDL Ratio Change 
 As expected, the HDL/LDL ratio change was primarily related to both HDL change 
(r(702) = .489, r2 = .239, p < .001) and LDL change over the course of treatment (r(702) = -.602, 
r2 = .362, p < .001). Amount of HDL/LDL ratio improvement varied significantly (t(696) = -
3.434, p = .001) by gender, however. Although men had poorer HDL/LDL ratios at admittance 
when compared to women, men improved more (M = .074, SD = .157) during treatment than did 
women (M = .031, SD = .161). Even with the more marked improvement, discharge HDL/LDL 
values were still lower for men (M = .501, SD = .243) than for women (M = .523, SD = .244); 
however, it is possible that with continued treatment the observed trend in men might eclipse the 
gender differences at the conclusion of treatment. 
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Discussion 
The positive effects of the 18 day holistic cholesterol treatment program are evident; 
every variable related to cardiovascular health (with the exception of HDL levels) evidenced 
improvement over the course of treatment. Although the nominal HDL levels decreased during 
treatment, the concurrent improvements in total cholesterol levels, LDL levels, and the 
HDL/LDL ratio help explain the observed phenomenon. A wide range of patients is represented 
in the sample yet improvements are seen, not just in the cholesterol profile, but also in blood 
pressure, weight, and pulse rate.  
As markers for cardiovascular health and CVD risk, both total cholesterol levels and the 
HDL/LDL ratio were analyzed in conjunction with other cardiovascular health-related variables 
such as blood pressure, weight, and amount of exercise. Both total cholesterol and the HDL/LDL 
ratio were most strongly related to changes evidenced in various components of the cholesterol 
profile (triglyceride and LDL levels, for example). Gender differences in the cholesterol profile 
were also noted. Although initial values for total cholesterol and HDL/LDL ratio were poorer for 
men than for women, men saw greater improvement in both of these variables than did women. 
The total cardiovascular health-related variable improvement during the treatment 
program, as well as the improvement in the cholesterol profile, provides evidence for a holistic 
perspective on cardiovascular treatment regimens. Because the population included in this study 
was quite large, only the greatest effect sizes were noted in this report; however, it is evident 
from an analysis of the data that a lifestyle program such as this has beneficial effects for a wide 
range of cardiovascular health-related variables. Even over the short duration of this program, 
mean cholesterol levels improved by 23.70 mg/dL, triglycerides by 27.72 mg/dL, and systolic 
blood pressure by 14.48 mmHg.  
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This study opens doors for future holistic research into alternative methods of cholesterol 
treatment. Notwithstanding, there are some limitations to the design of the study. First, because 
the data in this study are archival, the reasons for which patients sought treatment at the program 
are unknown, and the profile of patients treated may not be representative of the population 
seeking statin treatment. Additionally, in quite a few patients, at least one data point was missing 
from the record; although the statistical analysis was possible due to the large sample size, the 
missing data points may have restricted the holistic perspective of each patient’s health changes. 
Patient data was also collected over a period of time and by various physicians. This may have 
introduced some error and variability into the data aggregated.  
Future research possibilities include replication studies at other holistic cholesterol 
treatment centers, a mixed study design investigating both the psychological and physiological 
factors associated with holistic treatment programs, and an experimental study to control for the 
difference in environment at the treatment center versus implementing the same lifestyle changes 
in the patients’ homes. While this study is by no means exhaustive, it aims to provide a basis for 
choosing a holistic treatment program as an alternative to traditional statin treatments, and works 
to establish a holistic understanding of cardiovascular health due to simple lifestyle changes. 
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Table 1 
Summary of Patient Record Data at Admittance 
Variable M SD # Valid cases 
Total cholesterol (mg/dL) 197.61 47.31 844 
Triglycerides (mg/dL) 180.60 116.06 843 
HDL (mg/dL) 47.90 14.29 842 
LDL (mg/dL) 113.83 36.57 794 
HDL/LDL ratio 0.47 0.23 793 
Systolic blood pressure (mmHg) 141.22 24.79 888 
Diastolic blood pressure (mmHg) 79.98 14.44 892 
Pulse rate (beats/minute) 76.15 12.22 889 
Weight (lbs) 204.70 62.55 893 
Exercise (miles/day) .825 1.41 739 
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Table 2 
Summary of Gender Differences in Cardiovascular Health Variables at Admittance 
   Means 
Variable t-statistic p-value Men (SD) Women (SD) 
Total cholesterol (mg/dL) 4.988 .000 187.33 (47.03) 203.90 (46.57) 
Triglycerides (mg/dL) -1.658 n.s. 189.12 (123.15) 175.41 (111.81) 
HDL (mg/dL) 11.492 .000 41.53 (11.38) 51.85 (14.43) 
LDL (mg/dL) 3.678 .000 107.66 (35.59) 117.49 (36.81) 
HDL/LDL ratio 3.516 .000 0.435 (0.209) 0.494 (0.241) 
Systolic blood pressure 
(mmHg) 
1.165 n.s. 139.93 (24.40) 141.93 (25.05) 
Diastolic blood pressure 
(mmHg) 
-1.042 n.s. 80.62 (16.23) 79.54 (13.20) 
Pulse rate (beats/minute) 1.509 n.s. 75.42 (12.73) 76.69 (11.89) 
Weight (lbs) -6.962 .000 222.98 (65.18) 193.07 (57.85) 
Exercise (miles/day) -.958 n.s. 0.89 (1.40) 0.79 (1.42) 
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Table 3 
Interactions between Cholesterol, LDL, and HDL/LDL Ratio Changes when Predicting HDL 
Change 
 Unstandardized Coefficients    
Variable B SE β t-statistic p-value 
(Constant) -1.649 .274  -6.011 .000 
Cholesterol change .045 .014 .172 3.312 .001 
LDL change .127 .019 .389 6.785 .000 
HDL/LDL ratio change 38.197 1.702 .803 22.441 .000 
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Table 4 
Mean Change Scores in Cardiovascular Health Variables over the Course of Treatment 
Variable 
Mean change     
(discharge – admittance) SD t-statistic p-value 
Total cholesterol 
(mg/dL) 
-23.695 32.289 -20.270 .000 
Triglycerides (mg/dL) -27.723 80.923 -9.457 .000 
HDL (mg/dL) -2.596 8.318 -8.622 .000 
LDL (mg/dL) -16.165 23.356 -18.363 .000 
HDL/LDL ratio 0.047 0.160 7.793 .000 
Systolic blood pressure 
(mmHg) 
-14.484 19.196 -21.580 .000 
Diastolic blood pressure 
(mmHg) 
-6.979 12.008 -16.653 .000 
Pulse rate (beats/minute) -4.484 10.904 -11.624 .000 
Weight (lbs) -5.771 9.722 -17.121 .000 
Exercise (miles/day) 2.680 2.155 31.976 .000 
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Table 5 
Correlations Matrix for Total Cholesterol, HDL/LDL Ratio, and Additional Cardiovascular 
Health-related Variables 
 
Cholesterol at 
admittance 
Cholesterol 
change 
HDL/LDL at 
admittance 
HDL/LDL 
change 
1. Cholesterol at admittance —     
2. Cholesterol change -.476* —   
3. HDL/LDL at admittance -.433* .273* —  
4. HDL/LDL change .034 -.469* -.255* — 
5. Triglycerides at admittance .446* -.292* -.294* .036 
6. Triglyceride change -.292* .472* .121* -.213* 
7. HDL at admittance .190* .06 .623* -.196* 
8. HDL change -.063 .011 -.239* .489* 
9. LDL at admittance .884* -.371* -.630* .075 
10. LDL change -.370* .834* .353* -.602* 
11. Systolic BP at admittance .074 -.030 -.080 .005 
12. Systolic BP change -.006 .047 .011 .003 
13. Diastolic BP at admittance .136* -.094 -.159* .030 
14. Diastolic BP change -.051 .064 .084 -.035 
15. Pulse rate at admittance .113* -.081 .064 .044 
16. Pulse change -.049 .077 -.044 -.059 
17. Weight at admittance .047 -.161* -.246* .070 
18. Weight change -.007 .085 .099* -.030 
19. Exercise at admittance -.114* .029 .041 .037 
20. Exercise change .080 -.149* -.087 .069 
Note: * = Correlation is significant at the .01 level (2-tailed).  
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Figure 1 
Initial Total Cholesterol Means by Age Group 
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Figure 2 
Total Cholesterol Mean Changes by Age Group 
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